Expression pattern of PRDM family using tissue clearing technique in mouse micro-embryo by 강혜원
 
 
저 시-비 리- 경 지 2.0 한민  
는 아래  조건  르는 경 에 한하여 게 
l  저 물  복제, 포, 전송, 전시, 공연  송할 수 습니다.  
다 과 같  조건  라야 합니다: 
l 하는,  저 물  나 포  경 ,  저 물에 적 된 허락조건
 명확하게 나타내어야 합니다.  
l 저 터  허가를 면 러한 조건들  적 되지 않습니다.  
저 에 른  리는  내 에 하여 향  지 않습니다. 




저 시. 하는 원저 를 시하여야 합니다. 
비 리. 하는  저 물  리 목적  할 수 없습니다. 




Expression Pattern of PRDM Family 



























Kang, Hae Won 
 
Department of Medical Science 
 







Expression Pattern of PRDM Family 



























Kang, Hae Won 
 
Department of Medical Science 
 








Expression Pattern of PRDM Family 












The Master's Thesis submitted to  
the Department of Medical Science 
the Graduate School of Yonsei University in partial 
fulfillment of the requirements for the degree of 












This certifies that the Master's Thesis of 




          Thesis Supervisor : Cho, Yong Eun 
 
--------------------------------------------------------------- 
Thesis Committee Member#1 : Kim, Chul Hoon 
 
--------------------------------------------------------------- 















본 논문이 나오기 까지 열정과 끈기를 가지고 연구에 몰두해왔습니다. 
배움의 길이었던 수련과정동안 많은 조언과 지원을 해주신 조용은 
교수님 정말 감사드립니다. 
바쁘신 가운데서도 제 논문을 심사해주시고 아낌없는 격려를 해주신 
김철훈 교수님과 한인보 교수님께 감사드립니다. 
수련과정중에 격려와 조언으로 응원을 해주신 연구실에 우지원 
박사님께도 깊은 감사드립니다. 
또한, 저의 성장을 옆에서 함께 지켜보고, 힘이 들고 지칠 때 함께 
이야기하며 도움을 주고 할 수 있다고 응원해준 양유미연구원님, 
김유연연구원님, 그리고 박시내 선생님 감사드립니다.  
 
 















TABLE OF CONTENTS 
 
ABSTRACT ··········································································· 1 
 
I. INTRODUCTION ··································································· 3 
II. MATERIALS AND METHODS ················································· 6 
  1. Animals ··········································································· 6 
  2. Isolation of mouse tissue ······················································· 6 
  3. Generation of transparent embryos and CNS tissue ························· 7 
A. E13.5 embryos and brain tissue clearing using optimized passive 
clearing methods ······························································ 7 
    B. Optical clearing of E7.5-11.5 embryos using mPACT-A ··············· 7 
4. Immunostaining ································································· 8 
5. Image processing ································································ 9 
 
III. RESULTS  ········································································ 9 
  1. Generation of transparent mouse embryos using a modified passive clearing 
methods  ·········································································· 9 
  2. Development of embryo specific mPACT-A to achieve tissue clarity in 
early stage embryos ····························································· 11 
  3. PRDM12 expression in mouse embryo using mPACT-A ·················· 14 
4. Expression patterns of PRDM7 in mouse embryos at different stages ···· 15 
5. Expression patterns of PRDM8 and PRDM13 in transparent mouse 
embryos ··········································································· 17 
 
V. DISCUSSION  ····································································· 18 
V. CONCLUSION  ··································································· 21 
 
REFERENCES  ······································································· 22 
ABSTRACT (IN KOREAN)  ······················································· 25 
LIST OF FIGURES 
 
Figure 1. Generation of transparent mouse embryos via psPACT 
and mPACT-A ············································· 10 
 
Figure 2. Scheme representing the optimized mPACT-A for 
mouse embryo ············································ 11 
 
Figure 3. Stained blood vessels using the mPACT-A method  12 
 
Figure 4. Scheme representing the PRDM molecular structure 13 
 
Figure 5. Profiling of PRDM12 expression during early mouse 
development in intact embryos via mPACT-A at E9.5 
(A) and E10.5(B)  ········································ 14 
 
Figure 6. Representative PRDM7 gene expression image in 
mouse embryos at E9.5 and E10.5 ····················· 15 
 
Figure 7. Representative PRDM7 gene expression image of 
sagittal section E13.5 embryonic whole body ········ 16 
 
Figure 8. Representative PRDM13 and PRDM8 gene expression 
at E10.5 stage ·············································· 18 
 
LIST OF TABLES 
 







Expression Pattern of PRDM Family Using Tissue Clearing Technique in 
Mouse Micro-embryo 
 
Kang, Hae Won 
 
Department of Medical Science 
The Graduate School, Yonsei University  
 
(Directed by Professor Cho, Yong Eun) 
 
The proteins member of the PRDM family are known to have a potential role in 
tumor suppression, as well as in other diseases. Thus, elucidating the expression 
patterns of these PRDM proteins by high resolution analysis is necessary to 
future determine to characterize their biological role.  
Recent development in tissue clearing methods such as CLARITY (Clear 
Lipid-exchanged Acrylamide-hybridized Rigid Imaging/Immunostaining/In situ 
hybridization-compatible Tissue hYdrogel) has allowed for three-dimensional 
analyses of biological structures as a whole, intact tissue, providing greater 
understanding of spatial relationships and biological circuits. Nonetheless, 
studies have reported issues when it comes to maintain structural integrity and 
preventing tissue disintegration, discouraging the application of these 
techniques with fragile tissues such as developing embryos.  
Here, we present an optimized passive clearing technique, mPACT-A (modified 
PACT-Acrylamide), which improves tissue rigidity without the detriment to 
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optical transparency. The mPACT-A protocol is specifically optimized for 
handling mouse embryos, which are small and fragile and get easily dismantled 
when processed with established tissue clearing methods.  
We demonstrated the feasibility of this technique by investigating the 
expression of relatively understudied PRDM proteins, PRDM7, 8, 12 and 13, in 
intact cleared mouse embryos at different stages of development. We observed 
strong PRDM7, 8, 12 and 13 expression in the developing mouse nervous 
system in various development stages of the mouse embryos. These results 
suggest potential roles for the PRDM proteins in neural development, that 
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PRDI-BF1 and RIZ homology domain-containing (PRDM) proteins are a 
family whose members are defined by a conserved N-terminal PR domain and a 
variable number of zinc finger repeats in their C-terminus1-5. The PR domain 
shares homology with the catalytic SET domain that characterizes a large group 
of histone methyltransferases, and the zinc finger domains are known to be 
involved in DNA binding and protein-protein interactions3,6,7. Members of the 
PRDM family have been established as powerful transcriptional modulators, via 
either direct histone methylation or by recruiting other regulatory modulators to 
target promoters1,3,8.  
In primates, the PRDM family consists of 17 orthologous proteins, many of 
which are present in different molecular forms by alternative splicing or by the 
activation of alternative promoters1,2,7-15. This results in a highly diverse family 
of transcriptional modulators that play a variety of essential roles in 
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development and physiology3,6,7. Unsurprisingly, the dysregulated activity of 
PRDM proteins has widespread effects that result in disease and developmental 
defects. PRDM1, also known as BLIMP1 (B-lymphocyte-induced maturation 
protein 1), has been identified as a master regulator of terminal differentiation in 
B cells. PRDM3 and PRDM16 also play key roles in hematopoiesis and stem 
cell homeostasis1,8,11,13. Constitutive knockout of several PRDM proteins, 
including PRDM1, 3 and 16, are either embryonic or neonatally lethal11.  
PRDM family members have also been associated with oncogenesis, whereas 
some other members have been identified as potential tumor suppressors. For 
instance, hypermethylation of the PRDM5 promoter has been frequently 
observed in gastric carcinogenesis, and loss of PRDM2 has been associated 
with the development of blast crisis in chronic myeloid leukemia6,8,17. 
Nonetheless, a number of PRDM proteins remain to be characterized, with little 
information available about either their expression profiles or their functional 
relevance. For example, PRDM7, is a primate-specific histone 
methyltransferase that has been associated with Li-Fraumeni syndrome and 
resulted from the duplication of the PRDM9 gene17,18, which is the only hybrid 
sterility gene identified thus far in vertebrates. However, much still remains 
unknown regarding the roles of both proteins throughout development. The 
same occurs with the PRDM8 SET-domain, which is commonly located in the 
nucleus and is included as a specific HMTase (histone methyltransferase) 
proteins. Another members of the PRDM family are PRDM12, which has been 
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implicated in congenital pain insensitivity, and PRDM13, which is known to be 
expressed in the dorsal neural tube. While recent studies have shown that 
PRDM12 directs neuronal development towards the nociceptive neuron lineage, 
just a few of them have comprehensively assessed its expression throughout the 
course of embryonic development in vertebrates15,19.  
We recently developed two passive tissue clearing techniques (PACT), the 
process-separated PACT (psPACT) and the modified PACT (mPACT)20,21, 
derived from the original CLARITY (Clear Lipid-exchanged Acrylamide 
hybridized Rigid imaging/immunostaining/In situ hybridization compatible 
Tissue hYdrogel) method22 that allows for a three-dimensional microscopic 
analysis of intact whole tissue and organs. This technique has led to newfound 
understanding of cellular circuits in both physiological condition and disease, 
and allows for observation of subcellular structures, protein complexes, and 
biological networks with great spatial resolution. Compared to the original 
CLARITY method, psPACT and mPACT achieve tissue clearing with a greater 
transparency in a shorter timeframe. Nonetheless, it remains difficult to apply 
these techniques to more fragile tissues, such as those from developing mouse 
embryos. If possible, it could mean a great benefit to studies aiming to obtain 
three-dimensional information from these tissues. 
Here, we present an optimized version of our PACT protocol that improves 
tissue rigidity, without the detriment to optical transparency, which was termed 
mPACT-A. We also described an mPACT-A protocol that is specially geared 
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towards handling small mouse embryos, which easily disintegrate when 
processed by conventional clearing technique. Using this technique, we 
investigated the expression of PRDM 7, 8, 12 and 13 throughout mouse 
embryonic development. 
 
II. MATERIALS AND METHODS 
 
1. Animals 
Adult female BALB mice were purchased from Orient Inc. (Gyeonggi-do, 
Korea). Mouse embryos were isolated from E8.5 to E15.5 stages at the Cellular 
Reprogramming and Embryo Biotechnology Laboratory, in the Seoul National 
University’s School of Dentistry. All procedures were carried out in strict 
accordance with the recommendations provided by the Ministry of Agriculture, 
Food, and Rural Affairs (MAFRA) and were approved by Institutional Animal 
Care and Use Committee (IACUC) at Yonsei University.  
 
2. Isolation of mouse tissue  
Upon opening the mice thorax, an incision was made to the right atria of their 
hearts. Mice were then perfused with equal volumes of cold 0.1M 
phosphate-buffered saline (PBS) with 10unit/mL of heparine and 4% 
paraformaldehyde (PFA). Mouse embryos and central nervous system (CNS) 
tissue were then isolated using previously described methods. 
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3. Generation of the transparent embryos and CNS tissue 
A) E13.5 embryos and brain tissue clearing using optimized passive 
clearing methods 
Cultures were established from fixed mouse embryos and brain tissues on a 
clean bench. The sample of four modified PACTs (psPACT, mPACT, psPACT-A 
and mPACT-A) was transferred to sufficient 4% PFA solution to cover the tissue 
in a 50mL tube, and then stored at 4℃ for 24 hours. The fixed sample was 
washed for 1 hour with 0.1M PBS in a 50mL tube and then transferred to 
enough A4P0 solution (4% acrylamide in PBS) to cover the embry,o in a 50mL 
tube at 37℃ for 24 hours. Next, the sample was covered with 0.25% VA-044 
(Wako Pure Chemical Industries Ltd., Osaka, Japan) in 0.1M PBS in a 50mL 
tube at room temperature for 6 to 24 hours. The sample of mPACT-A was then 
transferred to A4P0. Then, the samples were embedded with nitrogen gas for 
10min, and the tissue was transferred to a 50mL tube containing clearing 
solution (8% SDS in 0.1M PBS, pH 8.0) with or without 0.5% α-thioglycerol 
(Sigma-Aldrich, Inc., MO, USA) in amounts enough to cover the sample; to 
then get incubated while shaking at 150rpm at 37℃ until the tissue cleared.  
 
B) Optical clearing of E7.5-11.5 embryos using mPACT-A 
Embryos were fixed in 4% PFA at 4℃ for 24 hours, and then washed with 0.1M 
PBS for 1 hour before being transferred to A4P0 at 37℃ for 6 hours. Embryos 
were then covered in 0.25% VA-044 at room temperature for 6 hours, exposed 
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to nitrogen gas for 10 min, and re-transferred to A4P0 at 37℃ for 6 hours. 
Finally, embryos were incubated in clearing solution (8% SDS in 0.1M PBS, pH 
8.0) with 0.5% α-thioglycerol at 37℃ in a shaking incubator at 150rpm until 
they achieved optical transparency. For more detailed instructions, see Figure 2.  
 
4. Immunostaining 
Cleared embryos were incubated in 0.1% Triton X-100 (Sigma-Aldrich, Inc., 
MO, USA) in 0.1M PBS for 2 hours, and blocked with 2% bovine serum 
albumin (BSA) in 0.1M PBS for 6 hours. Embryos were incubated with each 
PRDM 7, 8, 12 and 13 primary antibodies for 48 hours, followed by 3 washes in 
0.1% Tween-20 in 0.1M PBS (PBST) for 2 hours each. Then, they were then 
incubated in secondary antibodies, lectin dye, and DAPI in 2% BSA for 48 
hours. Then, nRIMS was prepared by mixing 0.8 g/mL of Nycodenz 
(Axis-shield Density Gradient Media, Oslo, Norway) in 30mL of base buffer 
(0.01% sodium azide and 0.1% Tween-20 in 0.1M PBS, pH 7.5). The labeled 
embryo was washed three times with PBST solution for 2 hours and stored in 
5mL of nRIMS solution for 2 days. After adding the nRIMS solution to the 
confocal dish, small embryos of E7.5-11.5 were incubated in nRIMS there for 
1-2 days, and covered using a coverslip with a diameter of 24mm. Detailed 





Table 1. Antibodies and dies information 
 
 
5. Imaging processing 
All clear images of embryos were captured using a digital camera (Canon 100D, 
Tokyo, Japan) and stereoscopic microscopes (SMZ745T; Nikon, Tokyo, Japan). 
Confocal microscopy was performed with an LSM-780 confocal microscope 
(Carl Zeiss, Oberkochen, Germany) at 10x magnification using the associated 
Zeiss software. Three dimensional images and videos were edited into serial 




1. Generation of transparent mouse embryos using a modified passive 
clearing methods 
To investigate the expression of PRDM 7, 8, 12 and 13 in intact embryos and 
CNS tissue, we sought to optimize our previously described psPACT and 
mPACT protocols to yield firmer tissue after clearing. The final steps of the 
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original psPACT and mPACT methods involve incubation of tissue in clearing 
solution consisting of just 8% (SDS) or 8% (SDS) with 0.5% α-thioglycerol, 
respectively. In this study, after embedding the tissue in 0.25% VA-044, we 
incubated tissues and embryos in A4P0 solution to improve the firmness of the 
resulting hydrogels, as shown in Figure 1A.  
As shown in Figure 1B and 1C, the addition of the second A4P0 incubation in 
mPACT-A yielded firmer tissue after achieving optical clearance, as measured 
by the degree of resistance to gravity.  
 
Figure1. Generation of transparent mouse embryos via psPACT and mPACT-A. 
(A) Scheme of psPACT, mPACT, psPACT-A and mPACT-A processes. (B) 
Brain 2mm clearing compare mPACT and mPACT-A. (C) Rigidity comparison 
between mPACT and mPACT-A. (D-G) Clearing of embryos at various 
developmental stages.     
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The improvement in tissue firmness was not at the expense of tissue clearance; 
as shown in Figure 1D, both psPACT-A and mPACT-A were able to achieve 
optical clearance of E13.5 mouse embryos within the same timeframe as the 
original protocols. Similar results were achieved for adult mouse brain, E8.5 
mouse chorions, and mouse embryos at E10.5 and E15.5 (Figure 1E-G). 
2.Development of embryo-specific mPACT-A to achieve tissue clarity in 
early stage embryos 
 
Figure 2. Scheme representing the optimized mPACT-A for mouse embryo. 
12 
 
In order to further optimize the mPACT-A method for mouse embryo during 
early development, we separate protocols for those between E7.5-E9.5 and 
E10.5-E11.5. In addition to the extra A4P0 incubation we added to the 
mPACT-A method, we added a second A4P0 incubation step after embryo 
embedding to improve tissue integrity.  
We also optimized our protocol in such a way that it would be suitable for 
manipulating small-sized tissue, as early-stage mouse embryos are often less 




Figure 3. Stained blood vessels using the mPACT-A method. (A) Images of 
cleared E8.5 embryos. (B) Images of cleared E9.5 embryos. (C) Images of 
Immunostained blood vessels (red) and nucleus (blue). 
 
As shown in Figure 3A and 3B, our embryo-specific mPACT-A protocol 
achieved tissue clearance in E8.5 and E9.5 mouse embryo after 12 and 24 hours, 
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respectively. Then, we tested the functional application of this technique by 
investigating early angiogenesis in E8.5 embryos with immunostaining for 
lectin during somitogenesis and notochord development. We were successfully 
able to generate z-stack images of blood vessel patterns throughout the entire 
mouse embryo at E8.5 (Figure 3C), and observed their organization around the 
neural folds and neural groove, as well as the primitive streak and developing 
somites. This result provided a proof-of-concept demonstration that our 
embryo-specific mPACT-A method can be used to perform three-dimensional 
analysis of biological structures in whole intact embryos. Next, we chose four 
PRDM proteins: PRMD7, 8, 12 and 13, which were expected to be expressed in 
the CNS of the mouse embryo. As shown in Figure 4, PRDM proteins have 
different molecular structure by PR domain and zinc fingers.  
 
 




3. PRDM12 expression in mouse embryos using mPACT-A 
 
Figure 5. Profiling of PRDM12 expression during early mouse development in 
intact embryos via mPACT-A at E9.5 (A) and E10.5 (B). 
 
PRDM family proteins function as either direct histone methyltransferase or 
modulators of epigenetic regulators, thus playing a variety of essential roles in 
physiology and development. Notably, PRDM12 has been implicated in 
congenital pain insensitivity, yet little is known about its expression profiles and 
biological functions in the developing vertebrate embryo. To investigate the 
expression pattern of PRDM12, we applied the mPACT-A technique to mouse 
embryos. At E9.5, PRDM12 was highly expressed in craniofacial structures and 
spinal cord, but its expression was also observed throughout the brain, 
especially in the optic vesicle, and the developing notochord (Figure 5A). At 
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E10.5, PRDM 12 expression continued to be observed in the developing CNS 
(Figure 5B). These results are in concordance with previous published studies 
on PRDM12 expression in mice. 
 
4. Expression patterns of PRDM 7 in mouse embryos at different stages 
 
Figure 6. Representative PRDM7 gene expression image in mouse embryo at 
E9.5 and E10.5. (A)At E9.5, PRDM7 expression is observed in somites and 




First, we investigated the body of an early mouse embryo (E9.5) to observe 
PRDM7 expression. We found that PRDM7 was expressed in spinal cord and 
somites (Figure 6A). 
Because this study represents the first time that PRDM7 expression is described, 
we sought to further investigate its expression profile throughout different 
stages and regions of the developing mouse embryo. As shown in Figure 6B 
and C, we observed PRDM7 expression in different tissues at E10.5, including 
in those where it had been previously observed, somites and notochord, but also 
the developing brain and the adrenal medulla. Strong expression was observed 
in the spinal cord, with segmental expression in the spinal ganglia.  
 
Figure 7. Representative PRDM7 gene expression image of sagittal section 




At E13.5, PRDM7 expression was still concentrated in the developing spinal 
cord and skeletal cartilage, but also observed in the lung, olfactory epithelium, 
adrenal medulla, the eye and the developing brain (Figure 7).  
Since these PRDM7 expressing tissue were mainly derived from mesodermal or 
neural crest cell populations, the results suggest that PRDM7 is consistently 
expressed for mesodermal differentiation during mouse development.  
 
5. Expression pattern of PRDM8 and PRDM13 in transparent mouse 
embryos 
We also examined the expression pattern of PRDM8 and PRDM13 at E10.5 
mouse embryos. As PRDM13 is known to be expressed in the dorsal neural tube, 
we expected to find PRDM13 also in the spinal cord, developing brain and tail 
region of mouse embryos. Our results showed that at E10.5, mPACT-A treated 
embryos had the PRDM13 expression concentrated in spinal cord, somites, 
neural tube and developing brain regions (Figure 8A).  
In Figure 8B, the expression pattern of PRDM8 shows this protein is produced 
in the dorsal neural tube, somites, spinal cord and developing brain regions at 
E10.5. Strong expression was observed in notochord, adrenal medulla and also 





Figure 8. Representative PRDM13 and PRDM8 gene expression at E10.5 stage. 




After applying the mPACT-A to mouse embryos, we demonstrated its viability 
by investigating the expression of four PRDM family proteins in mouse 
embryos, PRDM 7, 8, 12, and 13, which have been implicated in congenital 
disorders, but nonetheless are understudied compared with other PRDM 
proteins. 
As determined by a previous study, PRDM12 is known play a role in the 
development of neurons. Accordingly, we show that PRDM12 is expressed in 
the developing nervous system both at E9.5 and E10.5 including the notochord, 




We also observed PRDM7 expression primarily in craniofacial structures and 
neural structures such as notochord and the olfactory epithelium, with an 
especially high expression in the spinal ganglia. At E9.5, PRDM7 was 
expressed in the somites formation. At E10.5, PRDM7 was expressed in brain 
epithelium, spinal cord and concentrated in the neural tube. At E13.5, PRDM7 
expression was also observed in the lung, adrenal medulla and the eye. 
Comparing the pattern between each development stage, PRDM7 was 
concentrated in somite pairs and spinal cord at early stages, to then spread to 
developing brain regions and the CNS. Later, PRDM7 spread to the whole body, 
but kept concentrated in the spinal cord, somite pairs and brain regions which 
derived from the mesoderm. Notably, there are no previously published studies 
reporting tissue-specific PRDM7 expression, thus our study represents the first 
time in which PRDM7 expression is profiled.  
PRDM13 was examined at E10.5, and was found to be expressed in spinal cord, 
neural tube, somite pairs and developing brain epithelium. At the same stage, 
PRDM8 expression was found in the spinal cord, neural tube and developing 
brain regions.  
In a previous study, results of PRDM family expression patterns using in situ 
hybridization (ISH) assay, PRDM8, 12 and 13 were found to be highly 
expressed in the spinal cord region. Similarly, our results by using mPACT-A 
technique shows that PRDM8, 12 and 13 expression in spinal cord is as 
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concentrated, but also in neural tube and brain regions. Moreover, there were no 
previous studies about the expression pattern of PRDM7 in vertebrate 
development. We found it shows similar patterns in spinal cord, neural tube and 
developing brain regions in various development stages. Comparing with 
previous imaging studies, our mPACT-A technique could enable us to see 
specific regions such as the neural tube and somites, as well as the level of 
expression with high-resolution imaging. This level of resolution of expression 
level is possible since our mPACT-A technique clears the tissue while keeping it 
intact. As for PRDM12, it is known to have a role in the development of sensory 
neurons and it is expressed in the CNS. The high levels of PRDM expressions 
observed in the developing mouse nervous system suggest potential roles in 
neural development, which is represented in our result by using passive tissue 
clearing technique and high-resolution imaging analysis: PRDM7, 8, 12 and 13 













The development of a new tissue clearing technique allows the analysis of 
biological structures using three-dimensional intact organs. When used to study 
developing embryos, the mPACT-A technique showed greater rigidity after 
clearing. Also, a shorter time was required to apply it compared to PACT, 
obtaining the same degree of transparency. We demonstrated the feasibility of 
this modified technique by investigating the expression of PRDM 7, 8, 12 and 
13 which plays critical roles in vertebrate development, showing their 
expression in mesodermal regions, spinal cord, neural tube and developing 
brain regions as similar in each other. Future functional studies are needed to 
further characterize the biological role of PRDM7, 8, 12 and 13, whose role 
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PRDM 단백질군은 다양한 질병에서 종양억제제로서의 잠재적인 역할을 
한다고 알려져 있다. PRDM의 발현 양상을 고해상도로 분석하는 것은 훗날 
연구의 질병의 바이오 마커로써 사용 될 수 있는 PRDM의 발현 위치를 
확인 할 수 있다. 
CLARITY (Clear Lipid-exchanged Acrylamide-hybridized Rigid 
Imaging/Immunostaining/In situ hybridization-compatible Tissue 
hYdrogel) 과 같은 조직 투명화 방법의 개발은, 온전한 조직 전체에서 
생물학적 구조를 3차원적인 분석을 가능하게 하여 그들의 관계와 생물학적 
회로를 더 많이 이해할 수 있도록 합니다. 그럼에도 불구하고, 연구에 
따르면, 구조적인 안정성을 유지하며, 조직의 붕괴를 방지하여 발생 중의 
배아와 같은 연약한 조직에 이러한 기술의 적용을 할 수 없는 문제가 
보고되었다.  
본 연구는 투명화된 조직의 견고함을 향상시키고, 수동형 조직 투명화 
기술인 mPACT-A를 제시한다. mPACT-A 기술은 작고 연약한 쥐 배아를 
다루기에 특화하였다.  
본 연구는 다양한 쥐의 배발생단계에 따른 투명화된 쥐 배아에서 PRDM 
단백질군 중 PRDM7, -8, -12, -13 단백질들의 발현 양상을 비교적으로 
이해하기 위한 조사를 하였다. 
본 연구에서는 다양한 쥐 배아 발생 단계의 쥐 배아에서 신경계 발생 
과정에서 PRDM7, -8, -12, -13이 강하게 발현하는 것을 확인하였다. 이러한 
결과는 추가적인 기능적 연구들에 의하여 신경발생에 중요한 역할이 제시 
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